Nektar Therapeutics

Nektar Therapeutics reported a second-quarter 2026 loss of $1.23 per share, much narrower than the Zacks Consensus Estimate of a loss of $2.06 and the year-ago loss of $2.95 per share. Total revenues came in at $10.1 million, down 9.8% year over year and missing the consensus estimate of $11 million. The company's top line now consists solely of non-cash royalty revenues following the December 2024 sale of its Huntsville manufacturing facility. Nektar expects 2026 non-cash royalty revenues of $40-$45 million, R&D costs of $210-$230 million, G&A expenses of $60-$65 million, and year-end cash of approximately $815-$840 million. The company's lead candidate rezpegaldesleukin, or rezpeg, is advancing with two phase III studies in atopic dermatitis initiated last month and a third study scheduled to begin in September, with top-line data expected in mid-2028.

Applied Materials, Nektar Therapeutics, and StoneCo reported quarterly results, with Applied Materials posting adjusted earnings of $3.5 per share on revenues of $9.12 billion, beating the Zacks Consensus Estimate of $3.38 per share. Nektar Therapeutics reported a narrower-than-expected adjusted loss of $1.23 per share on revenues of $10.13 million, while StoneCo posted adjusted earnings of $0.47 per share on revenues of $709.88 million. The reports come as Wall Street heads for a winning week in which the S&P 500 recorded a new all-time high, and the Commerce Department said retail sales decreased 0.6% in July. After the closing bell, the University of Michigan will report its preliminary August consumer sentiment index, and the Census Bureau will release June business inventories data.